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The increasing incidence and severity of infection by Clostridium difficile have stimulated attempts to develop new antimicro-
bial therapies. We report here the relative abilities of two antibiotics (metronidazole and vancomycin) in current use for treating
C. difficile infection and of a third antimicrobial, surotomycin, to kill C. difficile cells at various stages of development and to
inhibit the production of the toxin proteins that are the major virulence factors. The results indicate that none of the drugs af-
fects the viability of spores at 8MIC or 80MIC and that all of the drugs kill exponential-phase cells when provided at 8
MIC. In contrast, none of the drugs killed stationary-phase cells or inhibited toxin production when provided at 8MIC and
neither vancomycin nor metronidazole killed stationary-phase cells when provided at 80MIC. Surotomycin, on the other
hand, did kill stationary-phase cells when provided at 80MIC but did so without inducing lysis.
In the United States, the incidence of Clostridium difficile infec-tion (CDI) has been steadily rising over the last 15 to 20 years
(1–3). There has been a significant increase in primary, recurrent,
and untreatable CDI on the global scale as well (3, 4). Treatment
with oral vancomycin or metronidazole, the current standard
practice, leads to recurrence of CDI in up to 30% of patients
treated for an initial episode. For patients who have already suf-
fered multiple recurrences, the future recurrence rate can be as
high as 60% (3, 5–7). In addition, many cases of CDI in the United
States are now linked to a family of more-virulent strains (NAP1/
BI/027) that emerged first in the United Kingdom and then in
Canada (8, 9).
C. difficile spores, the infectious form of the organism, are met-
abolically dormant but germinate in response to a combination of
host-derived bile acids and glycine (10). Because spores are met-
abolically dormant, they are insensitive to the action of most an-
tibiotics. Thus, after antibiotics are prescribed to treat the active
infection, the spores that remain in the colon or that are acquired
from the environment are able to germinate and reinitiate active
infection. The process of spore germination is largely enzymatic
and, once initiated, cannot be stopped. Once stimulated to germi-
nate, the spore releases a large depot of dipicolinic acid (DPA),
chelated 1:1 with Ca (Ca-DPA), in exchange for water (11).
Also, the cortex layer, a specialized peptidoglycan, is degraded (12,
13). After these changes, the spore is no longer dormant and does
not have the resistances typically characteristic of a spore. Metab-
olism then resumes within the spore core, and a vegetative cell
grows out from the germinated spore. Such outgrowth is suscep-
tible to the action of several antibiotics (14). Moreover, the host
intestine contains an assortment of antimicrobial compounds that
are produced by the innate immune system and the host microbi-
ota. To combat these defenses, C. difficile can modify its cell wall to
resist antimicrobials or efflux a variety of antimicrobial peptides
from the cell (15–17). These resistance mechanisms allow C. dif-
ficile to grow in the presence of antimicrobial peptides and may
also contribute to resistance to therapeutic antimicrobials.
Given the difficulties in treating C. difficile infections, the iden-
tification of narrow-spectrum antibiotics that are potent inhibi-
tors of C. difficile growth would fulfill a critical need. Also needed
are compounds or methods useful for reducing spore abundance
or viability in order to limit the onset of infection and to prevent
relapsing disease. Here we investigated the activities of a newly
developed antibiotic, surotomycin (18, 19), and compared its ac-
tivity to that of metronidazole and vancomycin, two antibiotics
that are currently used for treatment of C. difficile infections. Sur-
otomycin is a lipopeptide antibiotic that acts through depolariza-
tion of the membrane, leading to the loss of a proton gradient and
cell death (19). The mechanism of action of surotomycin differs
significantly from that of vancomycin (cell wall synthesis inhibi-
tion) and metronidazole (inhibition of cellular enzymatic func-
tions), suggesting that surotomycin may affect C. difficile physiol-
ogy differently from those other antibiotics. We report here the
relative sensitivities of C. difficile strains to surotomycin, metroni-
dazole, and vancomycin at multiple stages of the life cycle, i.e., as
dormant (phase-bright) spores, as germinated (phase-dark)
spores, as exponential-phase cells, and as stationary-phase cells. In
addition, we assessed the effects of the antibiotics on toxin gene
expression and measured the effects of various mutations that
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affect the sensitivity of exponential-phase cells to nisin (an antibi-
otic that creates holes in membranes and disrupts cell wall synthe-
sis) on susceptibility to the three tested compounds.
MATERIALS AND METHODS
Strains used and growth conditions. Clostridium difficile strains UK1
(ribotype 027; provided by D. Gerding) (20) and JIR8094 (ribotype 012;
provided by J. Rood) were routinely grown at 37°C in brain heart infusion
(BHI) medium supplemented with cysteine (0.1%) and yeast extract
(0.5%), referred to here as BHIS medium, or in tryptose-yeast extract
medium (3% tryptose, 2% yeast extract, 0.1% thioglycolate), referred to
here as TY medium. All growth experiments were performed in Coy an-
aerobic chambers in an atmosphere containing 85% nitrogen, 10% hy-
drogen, and 5% carbon dioxide as previously described (21, 22). Suscep-
tibility testing of surotomycin requires the presence of 50 mg (2.5 mEq)
Ca per liter in the medium (23). The levels of Ca in the media used
were determined by Laboratory Specialists Inc.; following their instruc-
tions, the Ca concentration in all media was raised to 50 mg/liter by
addition of CaCl2·2H2O. Drugs were added where indicated. Surotomy-
cin was provided by Cubist Pharmaceuticals. Metronidazole and vanco-
mycin were purchased from Sigma-Aldrich. Nisin was obtained from MP
Biomedicals.
The following mutant strains derived from JIR8094 were used in this
study: MC112, a lytC (peptidoglycan hydrolase), nisin-tolerant mutant;
MC119, a spontaneous cprK (nisin-resistant) mutant with increased re-
sistance to lantibiotics and polymyxin B (16); MC120, a mutant with a
TargeTron insertion in dltD resulting in increased susceptibility to nisin
and polymyxin B (15); and MC141, a mutant with a TargeTron insertion
in cprA causing increased susceptibility to lantibiotics (16).
MICs.MICs were determined by growth of bacteria in culture tubes or
in 96-well plates (that had been prereduced for at least 24 h prior to use) in
medium (either BHIS or TY) supplemented with 2-fold serial dilutions of
the test compounds. The initial bacterial titer was 5  105 CFU per ml.
Each strain and each drug concentration were tested in duplicate in each
MIC assay. The MIC was determined as the lowest concentration of drug
at which no bacterial growth was detected after 18 to 24 h at 37°C. MIC
assays were performed at least 3 times to ensure reproducibility of results.
Spore germination assay. Spores of C. difficile strain UK1 were pro-
duced and purified as described previously (14, 24, 25). Purified spores
(1 107) were suspended in 1 ml BHIS medium or germination salts [0.3
mM (NH4)2SO4, 6.6 mM KH2PO4, 15 mM NaCl, 59.5 mM NaHCO3, and
35.2 mM Na2HPO4] supplemented with 10 mM glycine. Cultures were
further supplemented with 2 mM taurocholic acid (TA) and the test com-
pounds at 8 or 80MIC. The initiation of spore germination was de-
tected as the loss of optical density at 600 nm (OD600) in a PerkinElmer
Lambda 25 spectrophotometer.
Measurements of killing rates. For experiments involving phase-dark
spores, 1 107 phase-bright spores of strain UK1 were first incubated for
10 min in BHIS medium supplemented with 2 mM TA. The suspension
was then centrifuged for 1 min at 14,000  g. The resulting pellet of
phase-dark spores was suspended in BHIS medium at a concentration of
1  105 per ml with or without the test compounds at 8 MIC or 80
MIC in Teflon-coated tubes to prevent the adherence of spores to the
tubes. Spores were confirmed to be phase-dark by phase-contrast micros-
copy. For experiments using exponential-phase vegetative cells, cells of
strain UK1 or JIR8094 (1 105 per ml) were suspended in BHIS medium
supplemented with CaCl2 with or without addition of the test compounds
at 8MIC for strain JIR8094 or at 8MIC and 80MIC for strain UK1.
For stationary-phase cell-killing assays, strain UK1 was grown in TY me-
dium for12 h and then diluted in 30 ml TY medium supplemented with
CaCl2 to give an OD600 of0.1. After 12 h of incubation at 37°C, at which
point the cells had left the exponential-growth phase, the culture was
subdivided and each of the test compounds was added to a separate cul-
ture tube at 8 or 80MIC. For all assays, samples were withdrawn at the
indicated time points thereafter and viability was scored by plating serial
dilutions on BHIS agar without calcium or antibiotic. Plates were incu-
bated in the anaerobic chamber overnight. Each killing-rate assay was
performed at least twice to ensure the reproducibility of the results.
Measurements of toxin gene expression. An overnight culture of
strain UK1 was diluted in 30 ml TY-Ca to give an OD600 of 0.1.
After 12 h of incubation at 37°C, the culture was split and each test
compound was added to a separate subculture at 8MIC. (Toxin gene
expression was not tested in cells exposed to drugs at 80MIC because
such treatment with surotomycin at that concentration led to cell
death and prevented the isolation of intact mRNA.) RNA was prepared
from cells harvested at 0, 2, 4, 8, and 24 h after addition of the drugs as
previously described (26). RNA was quantified by absorbance using a
NanoDrop ND-1000 spectrophotometer (Thermo Scientific). Primers
for quantitative PCR (qPCR) were designed using the online Primer-
Quest tool from Integrated DNA Technologies. Synthesis of cDNA was
performed on 500 ng of RNA using random hexamer primers and a
QuantiTect reverse transcription kit (Qiagen) according to the man-
ufacturer’s recommendations. To control for chromosomal DNA con-
tamination, mock cDNA synthesis reaction mixtures containing no
reverse transcriptase were used as negative controls in subsequent am-
plifications. cDNA samples were diluted 4-fold and used as the tem-
plates for qPCR of rpoC (primers oLB122 [CTAGCTGCTCCTAT-
GTCTCACATC] and oLB123 [CCAGTCTCTCCTGGATCAACTA])
and tcdA (primers oLB131 [GTATGGATAGGTGGAGAAGTCA] and
oLB132 [CTCTTCCTCTAGTAGCTGTAATGC]) using Roche SYBR
green I PCR mix and a Roche LightCycler 480 II thermocycler. Reac-
tions were performed in a final volume of 20 l using 4 l diluted
cDNA and primers at 1 M final concentration. Amplification in-
cluded 45 cycles of the following steps: 10 s at 95°C, 10 s at 52°C, and 15
s at 72°C. Reactions were performed in triplicate using cDNA synthe-
sized from each of a minimum of three biological replicates, and re-
sults are presented as the means and standard errors of the means
(SEM) of the data obtained. Results were calculated using the thresh-
old cycle (2CT) method, in which the amount of target mRNA is
normalized to that of an internal control transcript (rpoC) (27).
Measurements of toxin protein accumulation by ELISA.Culture su-
pernatants of the samples used for RNA extraction (see above) were as-
sayed for toxin A levels by enzyme-linked immunosorbent assay (ELISA)
TABLE 1 MICs of antimicrobial compoundsa
Strain (growth medium)
MIC (g/ml)
Surotomycin Metronidazole Vancomycin
UK1 (BHIS Ca) 1.5 0.5 0.3125
JIR8094 (BHIS Ca) 1 0.5 2
UK1 (TY Ca) 0.125 0.125 1
ATCC 70057 (TY Ca) 0.125–0.25 0.06–0.125 1
a The various strains were grown in the indicated media and assayed for susceptibility
to the indicated antibiotics provided in a series of 2-fold dilutions. The MIC was
defined as the lowest concentration of antibiotic that prevented measurable growth.
TABLE 2 MICs of antimicrobial compounds for mutant strainsa
Strain
MIC (g/ml)
Nisin Surotomycin Metronidazole Vancomycin
JIR8094 180 1 0.5 2
MC112 180 2 0.5 2
MC119 1440 2 0.5 4
MC120 90 1 0.5 2
MC141 90 1 0.5 2
a Each strain and each drug concentration were tested in cells growing in BHIS medium
in duplicate for each assay. Assays were performed at least 3 times to ensure
reproducibility of results.
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(28). In brief, 96-well plates were coated with antibody to toxin A (Novus
Biologicals) overnight at 4°C. After being washed with phosphate-buff-
ered saline (PBS) containing 0.1% Tween 20, the plates were incubated
with blocking agent and, after the agent was discarded, incubated with
culture fluid samples with or without dilution for 1 h at room tempera-
ture. After being washed with PBS-Tween, the plates were incubated with
secondary antibodies fused to horseradish peroxidase (HRP) (Gallus Im-
munotech, Inc.). After 1 h at room temperature, the plates were washed
again with PBS-Tween and mixed with peroxidase substrate for 40 min at
room temperature. The reactions were stopped with H2SO4, and the
OD450 was determined using a plate reader. Standard curves were gener-
ated using purified recombinant toxin A (29).
RESULTS
Determining the MICs of the test compounds. The MICs for
each of the test compounds were determined using exponential-
phase cells as the target. The MIC values varied according to the
strain being tested and the growth medium used (Table 1). For all
further experimentation, the concentration of each antibiotic
used was based on the MIC of that antibiotic in the strain to be
tested growing in the medium being used. The growth medium
chosen for each experiment was based on previous experimental
conditions.
MIC determination in mutant strains. A panel of mutant
strains derived from JIR8094 and altered in susceptibility to nisin
and other small, cationic antimicrobial peptides (CAMPs) was
tested for their susceptibility to surotomycin, metronidazole, and
vancomycin. As shown in Table 2, the strains had identical met-
ronidazole MIC values, but the surotomycin and vancomycin
MIC values differed slightly. MC112 has a mutation in an autoly-
FIG 1 Effect of antibiotic treatment on initiation of C. difficile spore germination. C. difficile UK1 spores were suspended in BHIS-Ca medium (black) or
medium supplemented with surotomycin at 8MIC (A) or 80MIC (B) or vancomycin or metronidazole at 8MIC (C) or 80MIC (D). Where indicated,
the medium was supplemented with taurocholic acid (TA), an activator of germination. The initiation of spore germination was detected by measuring the loss
of OD600. Experiments were performed in duplicate; the presented data represent one such experiment. Germination plots from the two experiments were
superimposable.
TABLE 3 Time required to reduce viability of C. difficile UK1 phase-dark spores and exponential-phase cells by 90%
Target
Time to 90% killing (h)
8MIC 80MIC
Surotomycin Metronidazole Vancomycin Surotomycin Metronidazole Vancomycin
UK1 phase-dark sporesa 3.33 7 7 2 3 5
UK1 exponential-phase cellsb 0.33 1.5 1.5 	0.33 0.66 1.33
a Tubes containing BHIS medium supplemented with CaCl2 and the indicated antibiotics (at 8MIC or 80MIC) were inoculated with phase-dark spores of strain UK1 and
tested, after various times of incubation, for survival by plating on BHIS medium.
b Exponential-phase cells of strain UK1 growing in BHIS medium supplemented with CaCl2 were exposed to two different concentrations (8MIC and 80MIC) of the indicated
antibiotics. Survival was assayed by plating serial dilutions on BHIS-Ca medium.
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sin that presumably alters the cell wall of the bacterium, resulting
in increased tolerance of nisin though not a higher MIC value.
(That is, MC112 survives exposure to higher concentrations of
nisin than does the parent strain but does not grow in the presence
of nisin.) MC112 had growth similar to that seen with the wild-
type parent in all antibiotics tested, including surotomycin, in
which the strain grew at a 2-fold-higher concentration.
MC119 carries a mutation in a regulatory protein that is known
to control an ABC-transporter system (cprABC). As a result, the
MC119 mutant has an extraordinarily high drug MIC value for
growth in nisin. In a previous study, we determined that MC119
also is less susceptible to polymyxin B (16). The MC119 strain had
a 2-fold-higher drug MIC for both vancomycin and surotomycin.
The strongly decreased susceptibility of MC119 to nisin and its
modestly decreased susceptibility to surotomycin and to vanco-
mycin are consistent with the hypothesis that this mutant is al-
tered in its response to antimicrobials that target the cell surface.
Effects of antibiotic exposure on the initiation of C. difficile
UK1 spore germination.To test if surotomycin or vancomycin or
metronidazole is able to affect C. difficile spore germination, pu-
rified spores of strain UK1 were incubated in BHIS-Ca me-
dium with or without the germinant taurocholic acid (TA) (10)
and with or without each of the antibiotics. The spores germi-
nated, as measured by loss of OD600, when suspended in BHIS-
Ca medium supplemented with 2 mM TA but not in the ab-
sence of TA (Fig. 1). (The loss of OD corresponds to the
conversion of spores from a birefringent [phase-bright] form to a
nonbirefringent [phase-dark] form.) The addition of surotomy-
cin or metronidazole or vancomycin at 8 or 80 MIC had no
effect, either positive or negative, on TA-dependent spore germi-
nation (Fig. 1). When similar experiments were performed in a
buffer containing TA and glycine, a cogerminant, the same lack of
effect of the antibiotics was seen (data not shown).
Effects of antibiotic exposure on germinated (phase-dark)
spores. To determine the time after spore germination at which
outgrowing vegetative cells become sensitive to the antibiotics, we
added antibiotics to germinated (phase-dark) spores in BHIS-
Ca medium and followed bacterial viability at intervals there-
after. The outgrowing cells lost viability more rapidly after expo-
sure to surotomycin than after exposure to the other drugs (Table
3). Note that this experiment did not distinguish between the time
needed for killing and the growth stage at which outgrowing veg-
etative cells become susceptible to the drugs.
Effects of surotomycin, metronidazole, and vancomycin on
exponential-phase cells. Strains UK1 and JIR8094 were grown at
37°C to the early exponential phase in BHIS-Camedium. After
the initial titer was determined, the cultures were divided and
inoculated with the test drugs at concentrations corresponding to
8 or 80MIC. Samples of each culture were taken at multiple
time points, and surviving cell titers were determined by serial
dilution and plating on BHIS-Ca medium supplemented with
taurocholic acid (TA). In exponential-phase cells of strain UK1,
surotomycin reduced viability by 90% more rapidly than did the
other drugs (Table 3). In exponential-phase cells of strain JIR8094,
surotomycin, metronidazole, and nisin were all rapid killers, whereas
vancomycin reduced viability more slowly (Fig. 2).
Effects of surotomycin, metronidazole, and vancomycin on
stationary-phase cells.After incubation of a culture of strain UK1
in TY plus CaCl2 at 37°C for 12 h, the culture was split and each
drug was added to a separate culture tube at 8 or 80 MIC.
Samples were harvested at various intervals for CFU counts and
OD600 readings. At 8MIC, none of the three drugs substantially
reduced the turbidity of the culture (apparent cell mass) or viabil-
ity (Fig. 3A and 4A). At 80MIC, however, surotomycin greatly
diminished the viability (but did not diminish cell mass signifi-
cantly, indicating killing without cell lysis), whereas vancomycin
and metronidazole had no detectable impact on cell mass or via-
bility (Fig. 3B and 4B).
Effects of surotomycin, metronidazole, and vancomycin on
toxin gene expression and toxin release. To test the effects of the
FIG 2 Effects of drugs at 8MIC on survival of exponential-phase cells of C.
difficile strain JIR8094. Exponential-phase cultures (OD600 
 0.45) in BHIS-
Ca were exposed to the three antibiotics, and samples withdrawn at indi-
cated times thereafter were assayed for viability (CFU/ml).
FIG 3 Effects of drugs on stationary-phase cells of strain UK1 as measured by cell mass. (A) Each drug was added at 8MIC to the cultures at the early stationary
phase. (B) Each drug was added at 80MIC to the cultures at the early stationary phase. At least 3 biological replicates were performed for each drug at each
concentration.
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various drugs on toxin production, cells at an early stage of the
stationary phase were exposed to the individual compounds at 8
MIC. At intervals thereafter, samples were harvested and RNA was
extracted for quantitation by quantitative reverse transcription-
PCR (qRT-PCR). As shown in Fig. 5, expression of tcdA, the gene
that encodes toxin A, increased with time to similar extents in
untreated cells and cells treated with drugs.
To measure toxin A release into the culture medium, the su-
pernatant fluids of the samples used for RNA extraction as de-
scribed above were assayed for toxin A levels by ELISA (see Mate-
rials and Methods). Standard curves were generated using purified
toxin A. As shown in Fig. 6, the amount of toxin A in the culture
fluid was not significantly altered compared to the amount seen
with the no-drug control by exposure to surotomycin or metro-
nidazole at 8 MIC at the early stationary phase. Addition of
vancomycin, however, reduced toxin release at 24 h.
DISCUSSION
The results presented here show that surotomycin kills cells that
are growing out of germinated spores, exponential-phase cells,
and stationary-phase cells (in the latter case at 80MIC only) of
strain UK1 more rapidly than does metronidazole or vancomycin.
Surotomycin is also a more rapid killer of exponential-phase cells
of strain JIR8094 than is vancomycin. None of the antibiotics
tested was able to inhibit or activate C. difficile spore germination.
This result seems to fit with the mechanisms of action of the tested
antibiotics. The initiation of spore germination, a mostly enzy-
matic process, would be unaffected by antibiotics that need to be
metabolized before becoming potent (metronidazole) or by anti-
biotics that inhibit new cell wall synthesis (vancomycin). Suroto-
mycin leads to loss of the proton gradient but does so by depolar-
izing the membrane without causing permeability of molecules as
large as 671 Da (19). Such a mechanism might explain its lack of
effect on the initiation of spore germination if the pores created
are also not large enough to allow the escape of Ca-DPA from
the spore core, a step necessary for the completion of germination
(12, 13). Alternatively, surotomycin might be unable to penetrate
the spore coat and cortex in order to gain access to the spore inner
membrane.
Since outgrowing spores are metabolically active and synthe-
size new cell wall peptidoglycan, it is not surprising that such
spores are susceptible to all of the antibiotics tested, although the
heightened susceptibility of such cells to surotomycin was not
predictable. The greater activity of surotomycin may be due to its
ability to prevent the generation of the proton gradient needed for
metabolic functions to resume. After the loss of dormancy, me-
tabolism resumes in the core. Subsequently, a vegetative cell be-
gins to grow from the germinated spore and this requires new cell
wall synthesis. Metronidazole, which requires cellular metabolism
FIG 4 Effects of drugs at 8 and 80MIC on the viability of strain UK1 stationary-phase cells. Early stationary-phase cells were exposed to antibiotics at 8
MIC (A) or 80MIC (B). At the indicated time points thereafter, samples were removed and plated for viable counts (CFU).
FIG 5 qRT-PCR analysis of tcdA expression following treatment with suroto-
mycin, metronidazole, or vancomycin at 8 MIC. Strain UK1 was grown in
CaCl2-supplemented TY medium for12 h as described above, at which time
the culture was split and drugs were added at 8MIC. At 2, 4, 8, and 24 h after
addition of drugs, cell samples were harvested, RNA was extracted, and cDNA
was synthesized as described in Materials and Methods. cDNA corresponding
to tcdA mRNA was quantified by real-time PCR. Reactions were performed in
triplicate using cDNA synthesized from each of a minimum of three biological
replicates, and results are presented as the means and SEM of the data ob-
tained. Results were calculated using the threshold cycle (2CT) method, in
which the amount of target mRNA was normalized to that of an internal
control transcript (rpoC).
FIG 6 ELISAs of toxin A in cultures of strain UK1 treated with surotomycin,
metronidazole, or vancomycin at 8 MIC. Culture fluids of cells exposed to
antibiotics at the early stationary phase were collected at the indicated times
and assayed for toxin A by ELISA.
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for activity (30), inhibited growth in an intermediate time frame
with respect to surotomycin and vancomycin. Because new cell
wall synthesis occurs late during outgrowth, it is not surprising
that vancomycin required more time to inhibit growth than the
other two antibiotics tested.
Although the ability of all three antibiotics to kill exponential-
phase cells was expected, their differential effects on stationary-
phase cells suggest that surotomycin may be more effective than
vancomycin or metronidazole in reducing the severity and recur-
rence of infection. That is, at 80MIC, a relatively low dose com-
pared to those used clinically, surotomycin killed stationary-phase
cells rapidly. Since stationary-phase cells are the ones that form
spores and produce toxins, a drug that kills both exponential-
phase and stationary-phase cells may be particularly effective in
reducing the spore titer and toxin levels in the colon and in stool.
The appearance of C. difficile mutants that have decreased sus-
ceptibility to surotomycin is rare, and the MIC shift is not more
than 8-fold to 16-fold (18). Therefore, it is interesting that certain
mutant strains that were isolated on the basis of their increased
tolerance or resistance to nisin also showed slightly reduced sus-
ceptibility to surotomycin (Table 2). The basis for this decreased
susceptibility is not known but is likely to reflect changes in cell
surface architecture. The decrease in susceptibility gained, how-
ever, would not be expected to influence the effectiveness of sur-
otomycin in vivo.
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